- Company
- Decreased drug price and inclusion of impurities in Januvia
- by Jung, Sae-Im Jul 25, 2023 05:46am
- Nitrosamine impurities management hidden ambush... The standard will be significantly strengthened. The diabetes treatment 'Januvia series', for which sales rights were recently transferred to Chong Kun Dang, is experiencing sluggishness in the prescription market. Following last year's drug price cut, the company suffered voluntary withdrawals
- Company
- 'Paxlovid reduces the risk of deaths in high-risk groups'
- by Jung, Sae-Im Jul 25, 2023 05:45am
- ‘Paxlovid,’ the oral COVID-19 treatment used to prevent progression to severe COVID-19, has finally removed its ‘temporary’ approval tag, 1 year and 7 months after its introduction to Korea. Although the drug has now been officially approved as a new drug, it is still not being well utilized on-site. Therefore, whether the misunderstandings
- Company
- Cinqair’s quicker reimb renders reimb difficult for others
- by Eo, Yun-Ho Jul 25, 2023 05:45am
- Attention is rising on the progress of the two new asthma drugs that chose to receive reimbursement through the RSA track, unlike Cinquair. According to industry sources, GSK Korea’s ‘Nucala (mepolizumab)’ has recently been reviewed by the Health Insurance Review and Assessment Service’s Risk Sharing Agreement (RSA) subcommittee for r
- Company
- Original Forxiga’s sales strong despite generic entry
- by Kim, Jin-Gu Jul 24, 2023 05:26am
- Three months have passed since generic versions of the SGLT-2 inhibitor class diabetes treatment ‘Forxiga (dapaglifloin)’ were released en masse in Korea. Despite the release, the original product had successfully defended its lead, increasing outpatient prescriptions. The generic companies raised a combined prescription performance o
- Company
- CDK4/6 anticancer drug is very active in early breast cancer
- by Jung, Sae-Im Jul 24, 2023 05:25am
- The activity of CDK4/6 inhibitors in early breast cancer is not limited to Verzenio. Kisqali also presented data on adjuvant therapy after successful surgery at ASCO held in June. Although they are the same class of drugs, the clinical designs of the two drugs in early breast cancer are different in many ways. First, Verzenio was targeted for hi
- Company
- The synergy between strengths & strengths
- by Kim, Jin-Gu Jul 21, 2023 05:41am
- The number of domestic pharmaceutical companies collaborating to jointly sell drugs has increased significantly. In the past, drug co-promotion contracts were mainly concluded between multinational pharmaceutical companies and domestic pharmaceutical companies. In the pharmaceutical industry, it is interpreted as a result in which the need
- Company
- Exports of botulinum in the first half rose by 26%
- by Kim, Jin-Gu Jul 21, 2023 05:41am
- In the first half of last year, exports of domestic botulinum toxin increased by 26% compared to the previous year. In particular, exports to Brazil increased significantly. In the pharmaceutical industry, analysts say that Brazil is emerging as a major exporter of domestic botulinum toxin along with China and the United States. According to
- Company
- Korean pharmas busy recruiting talent from global pharmas
- by Lee, Seok-Jun Jul 21, 2023 05:41am
- Korea's pharmaceutical and bio businesses are busy recruiting talents from multinational pharmaceutical companies to further accelerate their global entry. Handok appointed Miyeon Kim (56) as the new CEO as of July 1st. At Pfizer, the new CEO Kim worked as the Strategic Planning Manager, Product Manager, Marketing Manager, and as the
- Company
- NHIS starts RSA reevaluations for AD drug Dupixent
- by Eo, Yun-Ho Jul 21, 2023 05:40am
- Sanofi has started reevaluation negotiations for its atopic dermatitis treatment ‘Dupixent,' which has been receiving reimbursement under the RSA (Risk Sharing Agreement). According to industry sources, Dupixent’s RSA term ends on December 31st, therefore, the drug is undergoing reevaluation negotiations with the National Health Insura
- Company
- MET-targeting Tepmetko lands in general hospitals in KOR
- by Eo, Yun-Ho Jul 20, 2023 05:34am
- The MET-targeted anticancer therapy ‘Tepmetko’ can now be prescribed at general hospitals in Korea. According to industry sources, ‘Tepmetko (tepotinib),’ a treatment for patients with locally advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations, passed the drug committees (DCs) of various medical inst
